Azitra, Inc. — Form 8-K
Filed July 15, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 24/100
What the filing says
Azitra announced preclinical ex vivo human skin tissue study results for ATR-COSF, a supernatant-based cosmetic ingredient containing recombinant human filaggrin domain (rHDfilaggrin). Two studies showed: (1) repeat-dose penetration into stratum granulosum layers improved versus single-dose; (2) dose-dependent elasticity improvement up to 4.4-fold at 7.5% w/w concentration, with 0.3% formulation achieving ~2x elasticity versus placebo. No financial figures, partnership deals, or clinical trial initiation announced—purely preclinical cosmetics data ahead of planned human studies.
Why this rating
Preclinical cosmetic ingredient data only; no revenue, partnership, or clinical trial announcement. Routine R&D progress for $4.7M-cap company; immaterial to business trajectory absent human trial initiation or commercialization event.
See more from July 15, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.